Giridharan Ramsingh

Giri Ramsingh, MD, is Vice President, Clinical Science at Obsidian Therapeutics, leading clinical development and translational science for next-generation cell therapies in oncology. A board-certified medical oncologist, he has held leadership roles at Gilead Sciences, Genentech/Roche, and Exelixis, advancing therapies across hematologic malignancies and solid tumors. His work has contributed to the development of approved and investigational cancer therapies, including venetoclax-based regimens in AML. Dr. Ramsingh trained and served on faculty at Washington University and the University of Southern California and has authored numerous scientific publications.